ALXO vs GILD
ALXO: An early-stage immuno-oncology biotech advancing a next-generation CD47 blocker designed to restore macrophage tumor-killing when combined with targeted cancer therapies. GILD: A diversified biopharmaceutical company pioneering viral disease treatments, cell therapies, and oncology medicines with a portfolio spanning HIV, hepatitis, and cancer.
Side-by-side fundamentals
| Metric | ALXO | GILD | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $2.02 | $130.34 | |
| Market cap as of 2026-07-23 | $272M | $163.6B | |
| P/E as of 2026-07-23 | n/a | 17.75 | |
| PEG as of 2026-07-23 | n/a | 1.94 | |
| Net margin as of 2026-07-23 | -753.5% | +31.0% | GILD higher |
| Gross margin as of 2026-07-23 | +9.0% | +79.3% | GILD higher |
| Operating margin as of 2026-07-23 | -732.0% | +34.9% | GILD higher |
| ROE as of 2026-07-23 | -124.1% | +42.2% | GILD higher |
| ROA as of 2026-07-23 | -85.6% | +16.1% | GILD higher |
| Debt / equity as of 2026-07-23 | 0.07 | 0.94 | ALXO lower |
| Revenue growth (YoY) as of 2026-07-23 | n/a | +3.5% | |
| Revenue CAGR (3y) SEC XBRL | n/a | +2.6% | |
| Dividend yield as of 2026-07-23 | n/a | +2.5% | |
| Dividend streak (yrs) SEC XBRL | n/a | 5 | |
| Beta as of 2026-07-23 | 0.39 | 0.34 | |
| 1-year return as of 2026-07-22 close | +327.1% | +18.3% | ALXO higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.